BD Pharmingen™ Purified Mouse Anti-Human p16 with Control
(RUO)
Description
Cyclins and cyclin-dependent kinases (cdks) form active complexes that regulate key events during the progression of the cell cycle and are evolutionarily highly conserved. The p16 protein has been identified as a specific inhibitor of cdk4 because it blocks cdk4 substrate phosphorylation. p16 inhibits cdk4 dependent phosphorylation of the tumor suppressor retinoblastoma protein (Rb) and Rb related proteins, p107 and p130. The biochemical properties of p16 suggest that it may be a tumor suppressor gene product. Recently a gene cloned from the short arm of human chromosome 9, Multiple Tumor Suppressor 1 (MTS1) has been identified as the gene for p16. The gene, now also known as the CDKN2 gene, has been found to be mutated in a very high percentage of tumors, including 75% of melanoma cell lines.
Preparation And Storage
Store both the Purified Mouse Anti-Human p16 antibody (component 51-1325GR) and the HeLa control lysate (component 51-16516N) undiluted at -20°C.
Recommended Assay Procedures
Western blot: For additional protocols on Western blotting, please refer to "Cell Biology (WB, IP, IHC, IF)" at our website: http://www.bdbiosciences.com/us/s/resources
Endogenous p16 has been detected in several cell lines including Saos-2 human osteosarcoma (ATCC HTB-85), WI-38 human lung fibroblast (ATCC CCL-75), HeLa cervical carcinoma (ATCC CCL-2) and 293 adenovirus immortalized human kidney (ATCC CRL-1573) cells. U-2 OS human osteosarcoma (ATCC HTB-96) and MCF7 human breast carcinoma (ATCC HTB-22) have been reported to have undetectable levels of p16 and are suggested as negative controls.
The differential tissue expression of p16 remains to be characterized by immunohistochemistry. Yeager et al. has reported p16 to be both nuclear and cytoplasmic in melanoma.
Product Notices
- Since applications vary, each investigator should titrate the reagent to obtain optimal results.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- Sodium azide is a reversible inhibitor of oxidative metabolism; therefore, antibody preparations containing this preservative agent must not be used in cell cultures nor injected into animals. Sodium azide may be removed by washing stained cells or plate-bound antibody or dialyzing soluble antibody in sodium azide-free buffer. Since endotoxin may also affect the results of functional studies, we recommend the NA/LE (No Azide/Low Endotoxin) antibody format, if available, for in vitro and in vivo use.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
| Description | Quantity/Size | Part Number | EntrezGene ID |
|---|---|---|---|
| Purified Mouse Anti-Human p16 | 50 µg (3 ea) | 51-1325GR | N/A |
| HeLa Control Lysate | 50 µg (1 ea) | 51-16516N | N/A |
Development References (7)
-
Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994; 264(5157):436-440. (Biology). View Reference
-
Li Y, Nichols MA, Shay JW, Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res. 1994; 54(23):6078-6082. (Biology). View Reference
-
Marx J. Link to hereditary melanoma brightens mood for p16 gene. Science. 1994; 265(5177):1364-1365. (Biology). View Reference
-
Serrano M, Hannon GJ, Beach . A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993; 366(6456):704-707. (Immunogen). View Reference
-
Shapiro GI, Edwards CD, Kobzik L, et al. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res. 1995; 55(3):505-509. (Biology). View Reference
-
Tam SW, Shay JW, Pagano M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4. Cancer Res. 1994; 54(22):5816-5820. (Clone-specific: Immunohistochemistry). View Reference
-
Yeager T, Stadler W, Belair C, Puthenveettil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res. 1995; 55(3):493-497. (Clone-specific). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
